摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为0,包括立体异构体,互变异构体,代谢物和药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译:式(I)和(Ib)化合物,其中(i)X1为N,X 2为S,(ii)X1为CR7,X2为S,(iii)X1为N,X2为NR2,或(iv)X1为CR7, X 2为O,包括立体异构体,互变异构体,代谢物及其药学上可接受的盐,可用于抑制PI3K的δ同种型,以及用于治疗由脂质激酶如炎症,免疫学和癌症介导的病症。 公开了使用式I化合物在体外,原位和体内诊断,预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要:
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
摘要:
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R2, R3, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
摘要:
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R, R2, and R3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
摘要:
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.